Selected research
Industry Research
Asthma Preventive Industry Research Report 2026
Market perspective
The global Asthma Preventive market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Asthma Preventive is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Asthma Preventive is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Asthma Preventive is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Asthma Preventive include Novartis, Merck, Roche, Pfizer, GSK, Amgen, Astrazeneca, Sumitomo Dainippon Pharma and Chiesi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Asthma Preventive market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Asthma Preventive Market by Company
Novartis
Merck
Roche
Pfizer
GSK
Amgen
Astrazeneca
Sumitomo Dainippon Pharma
Chiesi
Boehringer Ingelheim
Biotest AG
Abbot
Asthma Preventive Segment by Type
Sodium Cromolyn
Prednisolone
Asthma Preventive Segment by Application
Children
Adult
Asthma Preventive Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Asthma Preventive market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Asthma Preventive and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Asthma Preventive.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Asthma Preventive manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Asthma Preventive by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Asthma Preventive in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Sodium Cromolyn
- Prednisolone
Applications
- Children
- Adult
Companies covered
- Novartis
- Merck
- Roche
- Pfizer
- GSK
- Amgen
- Astrazeneca
- Sumitomo Dainippon Pharma
- Chiesi
- Boehringer Ingelheim
- Biotest AG
- Abbot
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Asthma Preventive Market Size (2021-2032)
- 2.2.2 Global Asthma Preventive Sales (2021-2032)
- 2.2.3 Global Asthma Preventive Market Average Price (2021-2032)
- 2.3 Asthma Preventive by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Sodium Cromolyn
- 2.3.3 Prednisolone
- 2.4 Asthma Preventive by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Children
- 2.4.3 Adult
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Asthma Preventive Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Asthma Preventive Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Asthma Preventive Revenue of Manufacturers (2021-2026)
- 3.4 Global Asthma Preventive Average Price by Manufacturers (2021-2026)
- 3.5 Global Asthma Preventive Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Asthma Preventive, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Asthma Preventive, Product Type & Application
- 3.8 Global Manufacturers of Asthma Preventive, Established Date
- 3.9 Global Asthma Preventive Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis
- 4.1.1 Novartis Company Information
- 4.1.2 Novartis Business Overview
- 4.1.3 Novartis Asthma Preventive Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis Asthma Preventive Product Portfolio
- 4.1.5 Novartis Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck Asthma Preventive Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck Asthma Preventive Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 Roche
- 4.3.1 Roche Company Information
- 4.3.2 Roche Business Overview
- 4.3.3 Roche Asthma Preventive Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Roche Asthma Preventive Product Portfolio
- 4.3.5 Roche Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Asthma Preventive Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Asthma Preventive Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 GSK
- 4.5.1 GSK Company Information
- 4.5.2 GSK Business Overview
- 4.5.3 GSK Asthma Preventive Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GSK Asthma Preventive Product Portfolio
- 4.5.5 GSK Recent Developments
- 4.6 Amgen
- 4.6.1 Amgen Company Information
- 4.6.2 Amgen Business Overview
- 4.6.3 Amgen Asthma Preventive Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Amgen Asthma Preventive Product Portfolio
- 4.6.5 Amgen Recent Developments
- 4.7 Astrazeneca
- 4.7.1 Astrazeneca Company Information
- 4.7.2 Astrazeneca Business Overview
- 4.7.3 Astrazeneca Asthma Preventive Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Astrazeneca Asthma Preventive Product Portfolio
- 4.7.5 Astrazeneca Recent Developments
- 4.8 Sumitomo Dainippon Pharma
- 4.8.1 Sumitomo Dainippon Pharma Company Information
- 4.8.2 Sumitomo Dainippon Pharma Business Overview
- 4.8.3 Sumitomo Dainippon Pharma Asthma Preventive Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sumitomo Dainippon Pharma Asthma Preventive Product Portfolio
- 4.8.5 Sumitomo Dainippon Pharma Recent Developments
- 4.9 Chiesi
- 4.9.1 Chiesi Company Information
- 4.9.2 Chiesi Business Overview
- 4.9.3 Chiesi Asthma Preventive Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Chiesi Asthma Preventive Product Portfolio
- 4.9.5 Chiesi Recent Developments
- 4.10 Boehringer Ingelheim
- 4.10.1 Boehringer Ingelheim Company Information
- 4.10.2 Boehringer Ingelheim Business Overview
- 4.10.3 Boehringer Ingelheim Asthma Preventive Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Boehringer Ingelheim Asthma Preventive Product Portfolio
- 4.10.5 Boehringer Ingelheim Recent Developments
- 4.11 Biotest AG
- 4.11.1 Biotest AG Company Information
- 4.11.2 Biotest AG Business Overview
- 4.11.3 Biotest AG Asthma Preventive Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Biotest AG Asthma Preventive Product Portfolio
- 4.11.5 Biotest AG Recent Developments
- 4.12 Abbot
- 4.12.1 Abbot Company Information
- 4.12.2 Abbot Business Overview
- 4.12.3 Abbot Asthma Preventive Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Abbot Asthma Preventive Product Portfolio
- 4.12.5 Abbot Recent Developments
5 Global Asthma Preventive Market Scenario by Region
- 5.1 Global Asthma Preventive Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Asthma Preventive Sales by Region: 2021-2032
- 5.2.1 Global Asthma Preventive Sales by Region: 2021-2026
- 5.2.2 Global Asthma Preventive Sales by Region: 2027-2032
- 5.3 Global Asthma Preventive Revenue by Region: 2021-2032
- 5.3.1 Global Asthma Preventive Revenue by Region: 2021-2026
- 5.3.2 Global Asthma Preventive Revenue by Region: 2027-2032
- 5.4 North America Asthma Preventive Market Facts & Figures by Country
- 5.4.1 North America Asthma Preventive Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Asthma Preventive Sales by Country (2021-2032)
- 5.4.3 North America Asthma Preventive Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Asthma Preventive Market Facts & Figures by Country
- 5.5.1 Europe Asthma Preventive Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Asthma Preventive Sales by Country (2021-2032)
- 5.5.3 Europe Asthma Preventive Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Asthma Preventive Market Facts & Figures by Country
- 5.6.1 Asia Pacific Asthma Preventive Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Asthma Preventive Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Asthma Preventive Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Asthma Preventive Market Facts & Figures by Country
- 5.7.1 South America Asthma Preventive Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Asthma Preventive Sales by Country (2021-2032)
- 5.7.3 South America Asthma Preventive Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Asthma Preventive Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Asthma Preventive Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Asthma Preventive Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Asthma Preventive Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Asthma Preventive Sales by Type (2021-2032)
- 6.1.1 Global Asthma Preventive Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Asthma Preventive Sales Market Share by Type (2021-2032)
- 6.2 Global Asthma Preventive Revenue by Type (2021-2032)
- 6.2.1 Global Asthma Preventive Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Asthma Preventive Revenue Market Share by Type (2021-2032)
- 6.3 Global Asthma Preventive Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Asthma Preventive Sales by Application (2021-2032)
- 7.1.1 Global Asthma Preventive Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Asthma Preventive Sales Market Share by Application (2021-2032)
- 7.2 Global Asthma Preventive Revenue by Application (2021-2032)
- 7.2.1 Global Asthma Preventive Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Asthma Preventive Revenue Market Share by Application (2021-2032)
- 7.3 Global Asthma Preventive Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Asthma Preventive Value Chain Analysis
- 8.1.1 Asthma Preventive Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Asthma Preventive Production Mode & Process
- 8.2 Asthma Preventive Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Asthma Preventive Distributors
- 8.2.3 Asthma Preventive Customers
9 Global Asthma Preventive Analyzing Market Dynamics
- 9.1 Asthma Preventive Industry Trends
- 9.2 Asthma Preventive Industry Drivers
- 9.3 Asthma Preventive Industry Opportunities and Challenges
- 9.4 Asthma Preventive Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst